Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 7/20 | 0.41 |
| ▸ | SKP1 | P63208 | 7/20 | 0.41 |
| ▸ | SKP2 | Q13309 | 7/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 6/20 | 0.40 |
| ▸ | TGM2 | P21980 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.38 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.38 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | ACACA | Q13085 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3265618 | 0.92 | CNR1 (0.41) | CKS1BSKP1SKP2CNR1CHRM4 | |
| SCHEMBL240063 | 0.90 | CKS1B (0.48) | CKS1BSKP1SKP2CNR1ACACB | |
| SCHEMBL3268959 | 0.86 | SCD (0.42) | CHRM4 | |
| SCHEMBL3265574 | 0.85 | TPSAB1 (0.40) | CKS1BSKP1SKP2CHRM4CHRM2 | |
| SCHEMBL1728924 | 0.85 | CNR1 (0.47) | CKS1BSKP1SKP2CNR1CHRM4 | |
| SCHEMBL3266883 | 0.84 | CKS1B (0.47) | CKS1BSKP1SKP2CNR1HSD11B1 | |
| SCHEMBL3265698 | 0.84 | CHRM4 (0.48) | CKS1BSKP1SKP2CHRM4CHRM2 | |
| SCHEMBL240267 | 0.82 | PDE10A (0.44) | ACACBACACA | |
| SCHEMBL3266878 | 0.82 | CKS1B (0.45) | CKS1BSKP1SKP2CNR1 | |
| SCHEMBL3269876 | 0.81 | HRH3 (0.40) | CHRM4TGM2TPSAB1TPSD1TPSG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004207-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES | SANOFI-AVENTIS (FR) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004207-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES | CLCN2, CLIC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CKS1B 1534/4885SKP1 4286/4885SKP2 2651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.